Aventis's Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with ...

The FDA has approved Merilog, the first-ever rapid-acting insulin biosimilar for diabetes treatment that helps manage blood ...

Humulin R (insulin human) is a prescription drug that’s used ... Humulin R comes as a solution inside vials. The higher-strength version of the drug also comes in disposable, prefilled injection ...

The US Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart), ...

U-500 insulin human regular (Humulin R U-500 ... in a tuberculin syringe c rather than sending a 20-mL U-500 insulin vial to the floor for nurse preparation. "High-alert medication" labeling ...

Merilog is expected to be available in July 2025, and Sanofi will provide Merilog to patients for $35 or less for a 30-day ...

Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.

Merilog is a rapid-acting human insulin analog and the first rapid-acting ... Both a 3-mL single-patient-use prefilled pen and a 10-mL multiple-dose vial are included in this approval.

Aventis’ rapid-acting insulin biosimilar product Merilog for improvement of glycaemic control in patients with diabetes: Maryland Monday, February 17, 202 ...

The U.S. Food and Drug Administration approved Merilog as biosimilar to Novolog for the improvement of glycemic control in adults and pediatric ...